Physiological principles underlying the kidney targeting of renal nanomedicines.

Autor: Huang Y; Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA., Ning X; Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA., Ahrari S; Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA., Cai Q; Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Rajora N; Department of Internal Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Saxena R; Department of Internal Medicine, Division of Nephrology, University of Texas Southwestern Medical Center, Dallas, TX, USA., Yu M; Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA. mengxiao.yu@utdallas.edu., Zheng J; Department of Chemistry and Biochemistry, The University of Texas at Dallas, Richardson, TX, USA. jiezheng@utdallas.edu.; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA. jiezheng@utdallas.edu.
Jazyk: angličtina
Zdroj: Nature reviews. Nephrology [Nat Rev Nephrol] 2024 Jun; Vol. 20 (6), pp. 354-370. Date of Electronic Publication: 2024 Feb 26.
DOI: 10.1038/s41581-024-00819-z
Abstrakt: Kidney disease affects more than 10% of the global population and is associated with considerable morbidity and mortality, highlighting a need for new therapeutic options. Engineered nanoparticles for the treatment of kidney diseases (renal nanomedicines) represent one such option, enabling the delivery of targeted therapeutics to specific regions of the kidney. Although they are underdeveloped compared with nanomedicines for diseases such as cancer, findings from preclinical studies suggest that renal nanomedicines may hold promise. However, the physiological principles that govern the in vivo transport and interactions of renal nanomedicines differ from those of cancer nanomedicines, and thus a comprehensive understanding of these principles is needed to design nanomedicines that effectively and specifically target the kidney while ensuring biosafety in their future clinical translation. Herein, we summarize the current understanding of factors that influence the glomerular filtration, tubular uptake, tubular secretion and extrusion of nanoparticles, including size and charge dependency, and the role of specific transporters and processes such as endocytosis. We also describe how the transport and uptake of nanoparticles is altered by kidney disease and discuss strategic approaches by which nanoparticles may be harnessed for the detection and treatment of a variety of kidney diseases.
(© 2024. Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: